- The BMJ iPad app brings you the best of print and online, including live links to the latest news, blogs, video, and podcasts. Get the BMJ iPad app.
- Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
- Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days.
- OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper.
Latest podcast list
Tamiflu (oseltamivir) is a neuraminidase inhibitor, developed by Roche, for the treatment of seasonal and pandemic influenza. Yet for the first time a comprehensive review of the data, by independent researchers, has shown that the claims for Tamiflu’s effectiveness have been overestimated, and that harms have been underreported.
For the full history, including the latest articles and an interactive timeline visit bmj.com/tamiflu
Here is the audio of a recent press conference where researchers and the BMJ's editors describe the findings of that research, and the systematic regulatory failures those findings expose.
- Fiona Godlee - The BMJ editor in chief
- Carl Heneghan - Director of Oxford University's Centre for Evidence Based Medicine
- Peter Doshi - Assistant Professor of Pharmaceutical Health Services Research
- Elizabeth Loder - The BMJ clinical epidemiology editor
- David Tovey - Editor in chief, Cochrane Library
- Ben Goldacre - Founder of the AllTrials campaign
Mabel Chew, The BMJ's practice editor, talks to Tamara Pringsheim, a neurologist from the University of Calgary, about the use of triptans for acute treatment of migraine.
Read the full article:
Triptans for symptomatic treatment of migraine headache